HBs Ag and antibodies to hepatitis C virus in complicated chronic hepatic diseases in Gabon - 06/05/08
Jean-Luc Perret [1],
Jean-Baptiste Moussavou-Kombila [2],
Eric Delaporte [3],
Liliane-Flore Pemba [2],
Jean-Bruno Boguikouma [2],
Thierry Matton [4],
Bernard Larouze [5]
Voir les affiliationsBackground and objective |
The prevalence of HBs Ag and anti-HCV antibodies are high in the general population in Gabon. The aim of this study was to perform a case control study to determine the role of hepatitis B and C viruses in decompensated cirrhosis and hepatocellular carcinoma.
Methods |
Between October 1990 and June 1998, HBs Ag and anti-HCV antibodies were investigated in 1 204 newly hospitalized patients. Sixty-seven had decompensated cirrhosis, 38 had hepatocellular carcinoma and six an association of both diseases. Prevalences were compared with those in a group of 527 sex and age matched controls from the same cohort.
Results |
HBs Ag prevalence among cases was 35.1% (decompensated cirrhosis: 34.2%; hepatocellular carcinoma: 40.5%) and 12.5% among controls. Anti-HCV were detected in 32.4% of cases (decompensated cirrhosis: 34.2%; hepatocellular carcinoma: 28.6%) and in 20.1% of controls. Complicated chronic liver disease was linked to HBs Ag (OR = 11.3; IC: 4.8-26.7; cirrhosis: OR = 18; IC: 5.3-61.5; hepatocellular carcinoma: OR = 8.3; IC: 2.5-27.8) in patients from 15 to 34 years old. Above 45 years, complicated chronic liver disease was linked to anti-HCV antibodies (OR = 2.9; IC: 1.6-5.3; cirrhosis: OR = 2.8; IC: 1.4-5.8; hepatocellular carcinoma: OR = 3.2; IC: 1.1-9.5).
Conclusion |
Both Hepatitis B and C viruses are linked to complicated chronic liver disease in Gabon in an age-dependent manner.
Plan
© 2002 Elsevier Masson SAS. Tous droits réservés.
Vol 26 - N° 2
P. 131-135 - février 2002 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.